Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASER: 177Lu-PSMA-617 in Advanced Clear Cell Renal Cell Carcinoma
NCT06964958Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in clear cell renal cell carcinoma (ccRCC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 36 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06964958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964958.